Related Experiment Videos
Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin
A Jones-Lecointe1, P J Green, H A Lee
1Haematology Department, St. Mary's Hospital, Portsmouth, Hants, UK.
Human recombinant erythropoietin in full dose substantially raises the haemoglobin in patients with end stage renal disease on dialysis. In lower doses no or little rise in haemoglobin is achieved but the ferritin, often very high before treatment, is disproportionately lowered. The hormone therefore may be useful in reducing iron overload in other situations.
Human recombinant erythropoietin in full dose substantially raises the haemoglobin in patients with end stage renal disease on dialysis. In lower doses no or little rise in haemoglobin is achieved but the ferritin, often very high before treatment, is disproportionately lowered. The hormone therefore may be useful in reducing iron overload in other situations.